Targovax ASA (Targovax or the Company; OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors, announces the appointment of Dr. Torbjørn Furuseth as CFO, effective 24 September 2018. Dr. Erik Digman Wiklund, currently Targovax’s CFO, will become Chief Business Officer, replacing Michael Bogenstaetter
Turning cancer into a chronic disease
OpinionFollowing last year’s approval by the US FDA, the EU’s EMA has now also approved the first two T-cell-based immunotherapies against certain types of cancer. This marks the ultimate proof-of-concept for the acceptance of patient-individualised cellular immunotherapies. The regulatory authorities have moved fast, together with the companies and manufacturers, to bring these products to patients as quickly as possible. This is a good start but what does the future hold?
Pharming receives complete response letter from FDA
Latest NewsThe FDA has requested additional clincal data demonstrating that Pharming Group’s recombinant C1 esterase blocker Ruconest can prevent hereditary angioedema attacks (HAE).
Virion Appoints Vanessa King as President & CEO
AppointmentsVirion Biotherapeutics announced the appointments of Vanessa King, PhD, as President & Chief Executive Officer this week.
CRISPR Therapeutics and Viacyte launch diabetes partnership
Latest NewsCRISPR Therapeutics AG announced a development partnership with ViaCyte Inc to develop genome-edited pancreatic islet cells, which do not require immunosuppression, to treat diabetes.
Carl Bjartmar appointed as CMO for Ascelia Pharma
AppointmentsAscelia Pharma announced on Friday Spetember 14 that Carl Bjartmar, MD, PhD, has been appointed as new Chief Medical Officer (CMO) for Ascelia Pharma. Carl has most recently worked as CMO for Wilson Therapeutics.
Sanofi preparing label extension for dupilumab
Latest NewsPositive Phase 3 results with Sanofi/Regeneron‘s IL4/IL-13-targeting antibody dupilumab (Dupixent) in adolescents with moderate-to-severe atopic dermatitis will form the basis of a regulatory submission in this new patient population, according to announcements of Sanofi.
Torbjørn Furuseth joins Targovax as CFO
AppointmentsTargovax ASA (Targovax or the Company; OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors, announces the appointment of Dr. Torbjørn Furuseth as CFO, effective 24 September 2018. Dr. Erik Digman Wiklund, currently Targovax’s CFO, will become Chief Business Officer, replacing Michael Bogenstaetter
Calcium does not contribute to heart failure
Latest NewsSlowing the leak of Calcium leak into cardiomyocytes does not improve the pumping malfunction in heart failure, German cardiologists report in Science Translational Medicine.
Boehringer Ingelheim bags ViraT in €210m deal
Latest NewsEMBL Ventures has announced that its portfolio company ViraTherapeutics is set to be acquired by Boehringer Ingelheim in a €210m million (US$245m) transaction.
Johanna Ivaska joins Orion Corporation
AppointmentsJohanna Ivaska, Academy Professor of Biochemistry has been appointed Head & Vice President of Oncology Research in Orion Corporation as of 1 October 2018. Ivaska joins Orion from the University of Turku and will continue working also there with her internationally recognised research team.